FDA Approves Pembrolizumab Combination for Cervical Cancer

The FDA has granted approval to pembrolizumab (Keytruda®, Merck) in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent, or metastatic cervical cancer whose tumors express programmed death-ligand 1 (PD-L1). The FDA has also granted regular approval to single-agent pembrolizumab for patients with recurrent or metastatic cervical cancer whose tumors express PD-L1, with a combined positive score of ≥1, who experienced disease progression on or after c...

Keeping Abreast of Pharmacological Developments in Cancer Care: Perspectives from Teresa Knoop, MSN, RN, AOCN®

Teresa Knoop, MSN, RN, AOCN®.

At the Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit in Los Angeles, California, Teresa Knoop, MSN, RN, AOCN® gave a presentation on updates surrounding pharmacology. Oncology Data Advisor followed up with her, asking for advice on how to provide optimal pharmacological care for patients with cancer. 

Developments in Breast Imaging and Radiology: A Conversation With Tricia Trammell

Tricia Trammell, BA, CRA, FAHRA, R.T. (R)(M)(QM)(BS), CN-BI.

 In this interview, Tricia Trammell, BA, CRA, FAHRA, R.T. (R)(M)(QM)(BS), CN-BI, Breast Center Manager at UT Southwestern Simmons Comprehensive Cancer Center, discusses the advancements in breast imaging in relation to screening for breast cancer.

Managing the Care of Patients With Renal Cell Carcinoma During the COVID-19 Pandemic: Advice from Nazy Zomorodian, RNC, MSN, CUNP, CCRC

Nazy Zomorodian, RNC, MSN, CUNP, CCRC.
At the Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit in Los Angeles, California, Oncology Data Advisor spoke with Nazy Zomorodian, NP, a nurse practitioner in the Department of Urology at the University of California Los Angeles (UCLA) Medical Center, about strategies for optimizing patient experiences during renal cell carcinoma treatment. Ms. Zomorodian discusses the challenges of treating patients with renal cell carcinoma, particularly during the COVID-19 pandemic, and shares strategies for promoting adherence and optimizing treatment outcomes.

FDA Approves Cetuximab Plus Encorafenib for Metastatic Colorectal Cancer

 The FDA has granted approval to cetuximab (Erbitux®, Eli Lilly), in combination with encorafenib (Braftovi®, Array BioPharma) for the treatment of patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation. "Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy," wrote Scott Kopetz, MD, PhD, FACP, Professor in the Department of Gastrointestinal Medical ...

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.